MSC Therapy in Liver Transplantation

Status Recruiting

Clinical Trial Summary

The general aim of the present study is to test a cell therapy with third-party allogeneic ex-vivo expanded MSCs as a strategy to induce tolerance in liver transplant recipients. MSCs will be prepared accordingly to established protocols , starting from diagnostic samples of bone marrow aspirates (2-5 mL) or using the remnants in the bag and filter at the end of the bone marrow infusions. From these samples, MSCs will be expanded in GMP approved facilities and used for the present study in patients undergoing liver transplantation.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Liver Transplant Rejection

Clinical Trial Details

NCT number	NCT02260375
Study type	Interventional
Source	A.O. Ospedale Papa Giovanni XXIII
Contact	Giuseppe Remuzzi, MD
Phone	0039 0352674037
Email	gremuzzi@hpg23.it
Status	Recruiting
Phase	Phase 1
Start date	October 2014
Completion date	October 2025

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT01678937` - Immune Tolerance and Alloreactivity in Liver Transplant Recipients on Different Monotherapy Immunosuppressive Agents	N/A
Completed	`NCT03781414` - Study of Efficacy, Safety, Tolerability, Pharmacokinetic (PK) and Pharmacodynamic (PD) of an Anti-CD40 Monoclonal Antibody, CFZ533, in Liver Transplant Recipients With Additional 12-month Follow-up and Long-term Extension	Phase 2
Not yet recruiting	`NCT04514666` - VOCs in Kidney and Liver Transplants	N/A
Not yet recruiting	`NCT05335551` - TRU-IMMUNO: Optimizing Liver Immunosuppression
Completed	`NCT01745731` - Cell Infusion Intraportal Autologous Bone Marrow Mononuclear as Enhancer of Liver Regeneration	Phase 2
Enrolling by invitation	`NCT05082077` - Global Utilization And Registry Database for Improved preservAtion of doNor Livers
Completed	`NCT06060808` - Role of NFKBIA and PTPN22 Genes Polymorphism in Acute Rejection Susceptibility After Living Donor Liver Transplantation in Egyptian Patients.
Completed	`NCT03874286` - The TOGETHER Project - Liver
Completed	`NCT04789213` - Mortality, Morbidity and Risk Factors of Liver Retransplantation
Recruiting	`NCT06400771` - Safety of DNP007 in Healthy Subjects	Phase 1
Recruiting	`NCT03603548` - Comparison of Safety and Efficacy of Two Variants of Prolonged - Released Tacrolimus (Advagraf vs. Envarsus ) in Patients After Liver Transplantation : Single Center Randomised Control Trial	N/A
Withdrawn	`NCT03315052` - Budesonide for Immunosuppression After Liver Transplantation to Reduce Side Effects	Phase 4
Enrolling by invitation	`NCT05655273` - Conversion of Maintenance Prograf to Envarsus in Liver Transplant Recipients	Phase 4
Active, not recruiting	`NCT05325073` - Erythropoietin Therapy to Induce Regulatory T Cells in Liver Transplant Recipients	Phase 4
Recruiting	`NCT05707520` - Long-term Benefit of MPA in Liver Transplantation
Recruiting	`NCT04657562` - The New LC-MS/MS Method for Determination of Unbound Tacrolimus in Plasma
Completed	`NCT01444079` - Graft Rejection or Tolerance Affected by Serial Change of Anti-donor Lymphocyte Antibody After Liver Transplantation	N/A
Active, not recruiting	`NCT06153641` - Cytokeratin 18 Non-invasive Biomarker for Rejection in Liver Transplant Patients